L&C Bio , Ltd EBIT

As of the most recent data (June 2026), 290650.KQ shows a EBIT of $8.2B. That compares with $150B in the prior-year period — down 94.5% year over year. That is below the sector sector average of $2.6T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 290650.KQ's EBIT is now $8.2B (was $150B) — a 94.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether L&C Bio , Ltd is outperforming or lagging.

The its sector sector average EBIT is about $2.6T. L&C Bio , Ltd is at $8.2B, which is lower that average. That is roughly 99.7% below the sector mean. Use the comparison chart on this page to see how 290650.KQ stacks up against individual peers as well.

Tracking 290650.KQ's ebit over time shows whether L&C Bio , Ltd is scaling, shrinking, or reshaping that part of the business. The current reading is $8.2B That compares with $150B in the prior-year period — down 94.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has L&C Bio , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $8.2B) with ownership activity and broader fundamentals.